



Report Number: CAN-166-233-R
 Report Date: 21/06/22
 Report Status: Final
 Reported By: Matt Birt, Lead Scientist

Certificate of Analysis

British Cannabis
 Unit 3 Ashville Way
 Wokingham
 RG41 2PL

Sample Name: Elixinol Digest Capsules

Sample Code: CAN-166-233	Product Code: E0944727	Method: HPLC
Date Received: 16/06/22	Storage Conditions: Ambient	Date Tested: 18/06/22

Analysis		Result (%)
Cannabinoid Profile		
Cannabidiol (CBD)		1.920
Cannabidiolic acid (CBDa)		<0.003
Cannabidivarin (CBDV)		<0.003
Cannabigerol (CBG)		<0.003
Cannabigerolic acid (CBGa)		<0.003
Cannabinol (CBN)		<0.003
Tetrahydrocannabinolic acid (THCa)		<0.003
Δ -9-Tetrahydrocannabinol (Δ -9-THC)		<0.003
Δ -8-Tetrahydrocannabinol (Δ -8-THC)		<0.003
Cannabichromene (CBC)		<0.003
Tetrahydrocannabivarin (THCV)		<0.003

Method	Key	Testing Location
British Cannabis performs inhouse quantification of cannabinoids using HPLC-UV analysis on a Shimadzu Prominence-i LC-2030C Plus.	All results are displayed as percentage weight by weight and care should be taken to allow for the density of the product when calculating the final amount of cannabinoids in the product.	BRITISH CANNABIS Analytics 3 Ashville Way Wokingham RG41 2PL Berkshire (UK)

Released on behalf of BRITISH CANNABIS by
 Released by Matt Birt, Lead Scientist

This report and all information herein has been confirmed by the authorised person named above. The report should not be reproduced, except in its entirety, without written consent of the laboratory. Results are applicable only for the samples tested and the specific tests conducted. All tests are carried out under strict laboratory protocols, guidelines and supervision.

Comments and Interpretations
 Each finished product would contain an estimated 317mg of CBD.

All interpretations within this report are outside of accreditation scope and are provided as guidance only.
 Interpretation of results provided by
 Comments by Matt Birt, Lead Scientist